Experience in aneuploidies screening between 11-13+6 weeks with the Fetal Medicine Foundation algorithm

Authors

  • Roberto Albinagorta Olórtegui Ginecólogo Obstetra, Servicio de Medicina Fetal, Clínica Santa Isabel.
  • David Campodónico Olcese Ginecólogo Obstetra, Servicio de Medicina Fetal, Clínica Santa Isabel.

DOI:

https://doi.org/10.31403/rpgo.v59i33

Abstract

Objectives: To determine our experience in applying the Fetal Medicine Foundation (FMF) algorithm for first trimester aneuploidy screening in an unselected population. Design: Descriptive, retrospective, cross-sectional study. Setting: Fetal Medicine Service, Clinica Santa Isabel, Lima, Peru. Participants: Pregnant women and their fetuses. Interventions: Between March 1 and September 24 2012, nuchal translucency (NT) was measured by transabdominal ultrasound in 324 women with 11-13+6 weeks’ pregnancies and crown-rump length (CRL) between 45.0-84.0 mm. Main outcome measures: Factibility of FMF algorithm in 11-13+6 weeks screening. Results: NT curve in relation to CRLs was consistent with the quadratic equation described by FMF, and measurements followed a normal distribution with median deviation 0.2 mm lower than expected. The percentage of values above the median was 43.3%. A TN >95th percentile was observed in 4.6% of cases and TN ≥3.5 mm in 1.2%. A risk value above the 1:100 cut-off was found in 10 cases for T21 and in one case for T13. Cytogenetic study was performed in 3 patients; results were one normal female karyotype, one trisomy 18 and one extra-estructural trisomy (47XY+mar). Conclusions: Results agree with literature reports and show feasibility of FMF algorithm application in 11-13+6 weeks screening in a clinical practice setting in our country. Keywords: Ultrasound screening, aneuploidy, first trimester, nuchal translucency.

Downloads

Download data is not yet available.

References

Szabo J, Gellen J. Nuchal fluid accumulation in trisomy- 21 detected by vaginosonography in first trimester. Lancet. 1990;336:1133.

Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ. 1992;304:867-9.

Nadel A, Bromley B, Benacerraf BR. Nuchal thickening or cystic hygromas in first-and early second-trimester fetuses: prognosis and outcome. Obstet Gynecol. 1993;82:43-8.

Savoldelli G, Binkert F, Achermann J, Schmid W. Ultrasound screening for chromosomal anomalies in the first trimester of pregnancy. Prenat Diagn. 1993;13:513-8.

Pandya PP, Goldberg H, Walton B, Riddle A, Shelley S, Snijders RJ, et al. The implementation of first-trimester scanning at 10-13 weeks’ gestation and the measurement of fetal nuchal translucency thickness in two maternity units. Ultrasound Obstet Gynecol. 1995;5:20-5.

Braithwaite JM, Morris RW, Economides DL. Nuchal translucency measurements: frequency distribution and changes with gestation in a general population. Br J Obstet Gynaecol. 1996;103:1201-4.

Pandya PP, Santiago C, Snijders RJ, Nicolaides KH. First trimester fetal nuchal translucency. Curr Opin Obstet Gynecol. 1995;7:95-102.

Ramos D, Santiago JC, Castillo MJ, Montoya F. Translucencia nucal. Clin Invest Gin Obst. 2005;32(2):54-60. Snijders RJM, Nicolaides KH. Ultrasound markers for fetal chromosomal defects. Carnforth, UK: Parthenon Publishing; 1996.

Nicolaides KH. The 11-13+6 weeks scan. The Fetal Medicine Foundation, London, 2004.

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM; SURUSS Research Group. First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess. 2003;7:1-77.

Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS for Down’s syndrome associated pregnancy. Ann Clin Biochem. 1990;27 Pt 5:452-8.

Malone FD, Wald NJ, Canick JA, Ball RH, Nyberg DA, Comstock CH, et al. Use of overall population, centerspecific, and sonographer-specific nuchal translucency medians in Down syndrome screening: Which is best? (Results from the FASTER Trial). Am J Obstet Gynecol. 2003;189:S232.

ACOG Committee Opinion #296: First-trimester screening for fetal aneuploidy. Obstet Gynecol. 2004;104:215-7.

National Down’s Syndrome Screening Programme for England (2004) Antenatal screening-working standards. NHS.

NICE (2008) National Collaborating Centre for Women’s and Children’s Health. Commissioned by the National Institute for Clinical Excellence (NICE). Antenatal care: routine care for the healthy pregnant woman. London: RCOG Press.

Quispe J, Almandoz A, Michelena MQ. Translucencia nucal fetal, un marcador de alteraciones cromosómicas en el primer trimestre. Rev peru obstet ginecol. 1999;45(3):183-6.

Mejía JD. Translucencia nucal fetal en gestaciones únicas entre las 11-13+6 semanas, Instituto Nacional Materno Perinatal-año 2009 (Tesis de Especialista en Gineco- Obstetricia). Lima-Perú: UNMSM. 2011:37 pp.

Roberts LJ, Bewley S, Mackinson AM, Rodeck CH. First trimester fetal nuchal translucency: problems with screening the general population. Br J Obstet Gynaecol. 1995;102:381-5.

Braithwaite JM, Kadir RA, Pepera TA, Morris RW, Thompson PJ, Economides DL. Nuchal translucency measurement: training of potential examiners. Ultrasound Obstet Gynecol. 1996;8:192-5.

Pandya PP, Altman DG, Brizot ML, Pettersen H, Nicolaides KH. Repeatability of measurement of fetal nuchal translucency thickness. Ultrasound Obstet Gynecol. 1995;5:334-7.

Snijders RJ, Johnson S, Sebire NJ, Noble PL, Nicolaides KH. First-trimester ultrasound screening for chromosomal defects. Ultrasound Obstet Gynecol. 1996;7(3):216-26.

Nicolaides KH. Screening for chromosomal defects. Ultrasound Obstet Gynecol. 2003;21(4):313-21.

Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A. Hum Reprod. 2008;23(9):1968-75.

Snijders RJ, Thom EA, Zachary JM, Platt LD, Greene N, Jackson LG, et al. First trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol. 2002;19:353-59.

Published

2013-10-05

How to Cite

Olórtegui, R. A., & Olcese, D. C. (2013). Experience in aneuploidies screening between 11-13+6 weeks with the Fetal Medicine Foundation algorithm. The Peruvian Journal of Gynecology and Obstetrics, 59(3), 187–193. https://doi.org/10.31403/rpgo.v59i33

Issue

Section

Artículos Originales

Most read articles by the same author(s)